Table 3.

Patient characteristics at followup by RF status.

12 Months24 Months
CharacteristicAllnRF−nRF+npAllnRF−nRF+np
SJC28, median (range)1 (0–24)5140 (0–24)2441 (0–12)270NS0 (0–17)3610 (0–17)1740 (0–16)187NS
TJC28, median (range)1 (0–25)5141 (0–25)2441 (0–19)270NS0 (0–23)3610 (0–23)1740 (0–23)187NS
ESR, mean (SD)14.49 (14.88)51011.72 (11.35)24417.03 (17.14)266< 0.000114.98 (14)36712.89 (12.69)17816.94 (14.9)1890.0055
CRP, mean (SD), mg/l5.24 (7.91)5084.21 (6.81)2456.19 (8.72)2630.00455.47 (8.56)3674.62 (6.8)1776.27 (9.88)190NS
Erosions87 (27)32239 (25.7)15248 (28.2)170NS66 (26.7)24728 (24.1)11638 (29)131NS
DAS28, mean (SD)2.79 (1.29)4932.63 (1.22)2302.94 (1.34)2630.00932.71 (1.35)3472.58 (1.31)1662.82 (1.38)181NS
DAS28 < 2.6272 (52.3)520145 (58)250127 (47)2700.0124221 (58.8)376113 (62.1)182108 (55.7)194NS
HAQ, median (range)0.25 (0–3)5020.25 (0–2.38)2410.25 (0–3)261NS0.25 (0–2.5)3550.25 (0–2.5)1680.25 (0–2.38)187NS
RF-positive270 (51.9)520194 (51.6)376
Anti-CCP2-positive203 (62.3)32669 (45.4)152134 (77)174< 0.0001150 (60.5)24859 (47.6)12491 (73.7)124< 0.0001
1987 ACR RA criteria334 (65.4)511142 (58.4)243192 (71.6)2680.0017242 (64.9)373111 (61.3)181131 (68.2)192NS
2010 ACR/EULAR RA criteria373 (71.7)520160 (64)250213 (78.9)2700.0002278 (73.9)376123 (67.6)182155 (79.9)1940.0066
DMARD481 (93.6)514231 (94.7)244250 (92.6)270NS347 (93)373171 (95)180176 (91.2)193NS
Biologics50 (9.7)51429 (11.9)24421 (7.8)270NS55 (14.8)37337 (20.6)18018 (9.3)1930.0022
Corticosteroids122 (23.7)51456 (23)24466 (24.4)270NS94 (25.2)37338 (21.1)18056 (29)193NS
  • Anti-CCP: anticyclic citrullinated peptide; RF: rheumatoid factor; SJC28: swollen joint count-28; TJC28: tender joint count-28; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: Disease Activity Score-28; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; DMARD: disease-modifying antirheumatic drugs; NS: nonsignificant; HAQ: Health Assessment Questionnaire; RA: rheumatoid arthritis.